dydrogesterone การใช้

• The greater rigidity of dydrogesterone also positively affects its micronized progesterone.
• Progestins used for luteal support include dydrogesterone and 17?-hydroxyprogesterone caproate
• Dydrogesterone has selective progestational activity and does not inhibit ovulation.
• Dydrogesterone is used as an effective, orally active progestogen for synthesized progestogens.
• Unlike many other synthetic progestogens, dydrogesterone is not chemically related to testosterone.
• Dydrogesterone does not bind to the androgen receptor, estrogen receptor, or glucocorticoid receptor.
• As such, dydrogesterone does not undergo aromatisation, which is consistent with its absence of estrogenic effects.
• Furthermore, dydrogesterone does not undergo 17?-hydroxylation, which may contribute to its lack of androgenic effects.
• While the study did not involve dydrogesterone, it is possible, but not certain, that it too increases these risks.
• All the metabolites of dydrogesterone retain the 4, 6-diene-3-one structure, and are metabolically stable.
• Dydrogesterone when used therapeutically is closely related to its physiological action on the pre-menstrual syndrome and also as a hormone replacement therapy.
• Progesterone and non-androgenic progestins, such as dydrogesterone, do not affect serum IGF-1 levels regardless of route of administration.
• Dydrogesterone was first introduced, by Duphar, as Duphaston in the United Kingdom in 1961 . and Gynorest is also no longer available in the.
• Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate and norethisterone.
• Other progestogens including medroxyprogesterone acetate, lynestrenol, allylestrenol, dydrogesterone, and normethandrone have also been found to be effective for migraine in a high percentage of women.
• Progesterone ( or sometimes dydrogesterone or hydroxyprogesterone caproate ) is used for luteal support in preterm birth in pregnant women with a history of at least one spontaneous preterm birth.
• Dydrogesterone has also been registered as hormone replacement therapy ( HRT ) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus.
• Unlike progesterone, which forms sedative neurosteroid metabolites, dydrogesterone is not able to be metabolized in a similar way due to structural differences, and for this reason, is non-sedative.
• Pentagestrone acetate, along with quingestrone ( the 3-cyclopentyl enol ether of progesterone ), is said to have very similar properties to those of dydrogesterone, a pure progestogen and close analogue of progesterone.
• It is estimated that during the period from 1977 to 2005 around 38 million women were treated with dydrogesterone and that fetuses were exposed to dydrogesterone " in utero " in more than 10 million pregnancies.